HBV genotype and curative effect and prognosis related
April 21st, 2008 Guage
Antigen decision bunch of d which and y, w and r (HBV) the surface antigen HBsAg two pairs repel one another according to the hepatitis B virus, as well as HBsAg common antigen decision bunch of a, may branch out HBV 4 basic blood serums, namely adw, adr, ayw and ayr. But, blood serum’s division cannot reflect the HBV genome team the difference. According to the HBV entire gene nucleotide sequence different source ≥8% or the S gene area nucleotide sequence different source ≥4%, divide into different viral the different genotype, until now, HBV may divide into 8 genotypes, namely A, B, C, D, E, F, G and H.
Our country A, B, C, the D 4 genotypes exist, north city by gene C popular primarily, by the north to the south, the gene B infection percentage advances gradually, Shenzhen gene B and the C infection percentage proportion quite, national minority area gene D has the high infection percentage, Tibet by D primarily.
The clinical material demonstrated that the HBeAg elimination is possible and the HBV genotype concerns. Compares with the B genotype, the C genotype has the higher HBeAg masculine gender rate, respectively is 16% and 53%, even if according to the sex, the age, liver disease carries on the pair, similarly has the remarkable difference. Even thought that B genotype spontaneous HBeAg eliminates must compared to (genotype) early 10 years, and after the HBeAg elimination, the liver biochemistry target continues normally. After this difference is possibly causes the gene B infection and the gene C infection, one of clinical result different reasons.
After the different genotype HBV infection’s clinical condition weight, to the treatment response possibly is different. Domestic and foreign has the research discovery, in the specific weight chronic hepatitis, liver cirrhosis, liver cancer crowd, the gene C detection rate is higher than the gene B detection rate. After gene A and the gene B patient accept the interferon, the Lami husband decide the treatment, the HBeAg blood serum transfer ratio is high; But gene D/E and the gene C HBeAg blood serum transfer ratio are low. Moreover, after the gene B infected person has liver cancer, treats the response to embolism to surpass gene C, after embolism treats, the prognosis is good, does not have sends again; But in after control group’s C genotype patients have liver cancer, after embolism treats still continued to develop, dies finally of the liver failure. Because the HBV infection causes the last stage liver disease to accept the liver to transplant in finally the patient, after gene C and gene B transplant, infects sending rate to be again high.
In brief, must conduct more clinical researches and the experiment from now on, by determined whether needs to list as the genotype the clinical monitor target, instruction clinical care and prognosis judgment.
Related Posts
Entry Filed under: Liver Cancer
Leave a Comment
Some HTML allowed:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>
Trackback this post | Subscribe to comments via RSS Feed
. 